<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346697</url>
  </required_header>
  <id_info>
    <org_study_id>K23AT002862-01</org_study_id>
    <secondary_id>K23AT002862-01</secondary_id>
    <nct_id>NCT00346697</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of N-3 Fatty Acid on Plasma Triglyceride Levels in Hypertriglyceridemic HIV Patients Receiving Highly Active Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown, Todd, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown, Todd, M.D., Ph.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in
      HIV-infected patients with hypertriglyceridemia. In addition, we, the researchers, will
      evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and
      inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertriglyceridemia is common among HIV-infected patients receiving Highly Active
      Antiretroviral Therapy (HAART). Although fibrates, statins, and niacin have all been used in
      the management of hypertriglyceridemia in HIV-infected patients, optimal control is difficult
      to achieve and other agents are needed. Omega-3 fatty acids are effective for lowering
      triglycerides in patients without HIV infection, but experience in HIV-infected patients is
      limited. In addition, omega-3 fatty acids may also have secondary benefits in decreasing bone
      resorption and decreasing markers of systemic inflammation. The purpose of this study is to
      evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with
      hypertriglyceridemia. In addition, we will evaluate the effect of omega-3 fatty acid
      administration of markers of bone turnover and inflammation. It is 8- week randomized,
      double-blind trial of omega-3 fatty acids (LOVAZA, GSK, Inc) compared to placebo in 48
      HAART-treated HIV-infected patients with triglycerides between 250 and 1000 mg/dl receiving
      dietary counseling. Subjects will be recruited from three centers (Johns Hopkins, Georgetown,
      and Los Angeles VAMC). The primary endpoint will be the change in triglyceride concentrations
      from baseline in the LOVAZA group compared to the placebo group. Secondary endpoints include
      the effect of LOVAZA on other lipid targets (total cholesterol, LDL cholesterol,
      HDL-cholesterol), markers of systemic inflammation, markers of bone turnover, markers of
      insulin resistance, HIV-disease control (CD4+ counts, HIV viral loads), measures of
      hepatotoxicity (ALT), platelet function, and patient reports of adverse events. Omega-3 fatty
      acids may be a useful adjunct in the treatment of hypertriglyceridemia in HIV-infected
      patients, but additional controlled studies are needed to assess its safety and efficacy
      using a purified, standardized preparation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Triglyceride Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Non-HDL Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR From Baseline in the LOVAZA Group Compared to the Placebo Group</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T-cell Counts From Baseline in the LOVAZA Group Compared to the Placebo Group</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IL-6 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TNF-a Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sTNFR1 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sTNFR2 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CTX Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in P1NP Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Collagen ADP From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Collagen Epinephrine From Baseline in the LOVAZA Group Compared to the Placebo Group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <condition>Dyslipidemia</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>LOVAZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Corn oil placebo, plus dietary counselling</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acid administration</intervention_name>
    <description>LOVAZA 1 gram capsules, 4 capsules daily</description>
    <arm_group_label>LOVAZA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Corn-oil placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness to give informed consent

          -  Age â‰¥ 18 years

          -  HIV-1 infection documented at any time prior to study entry

          -  Fasting plasma triglyceride value between 200 and 1000 mg/dL on two occasions within 4
             weeks

          -  Subjects must be receiving a stable antiretroviral medication regimen for &gt; 3 months
             without any anticipated changes during the study interval

          -  Females must not be pregnant or lactating. Females of childbearing potential and males
             must use a reliable means of contraception

          -  On stable lipid modification pharmacotherapy for at least 8 weeks prior to study entry

        Exclusion Criteria

          -  Hemoglobin A1C &gt; 8.5 %

          -  Uncontrolled hypothyroidism (TSH &gt; 4.5)

          -  HIV viral load &gt; 5,000 copies/ml (cpm),

          -  Active liver disease and/or liver transaminases greater than 2.0 X upper limit of
             normal

          -  Active kidney disease or serum creatinine &gt; 2.5 mg/dL

          -  Myocardial infarction, unstable ischemic heart disease, stroke, or coronary
             revascularization procedure

          -  Uncontrolled hypertension within 4 weeks of study entry (SBP &gt; 180 mmHg or DBP &gt; 100
             mmHg)

          -  Use of systemic cancer chemotherapy within 8 weeks of study entry

          -  Pregnancy or breastfeeding

          -  Drug or alcohol dependence, or other conditions which may affect study compliance

          -  History of coagulopathy or use of anticoagulants such as warfarin

          -  Use of omega-3 fatty acid preparation in the 12 weeks prior to randomization

          -  Significant changes in clinical status from the Screening Visit which would preclude
             the patient from being an appropriate candidate.

          -  Any of the following laboratory parameters: hematocrit &lt; 25%, absolute neutrophil
             count &lt; 1.5 x 10^9/L, platelets &lt; 100 x 10^9/L or hemoglobin &lt; 8.0 gm/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd T. Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Leaf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Adminstration of Greater Los Angeles Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mattew Goetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Adminstration of Greater Los Angeles Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian S Dobs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Timpone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Administration of Greater Los Angeles Health System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Metkus TS, Timpone J, Leaf D, Bidwell Goetz M, Harris WS, Brown TT. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients. HIV Med. 2013 Oct;14(9):530-9. doi: 10.1111/hiv.12046. Epub 2013 May 19.</citation>
    <PMID>23683266</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>June 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2006</study_first_posted>
  <results_first_submitted>July 15, 2014</results_first_submitted>
  <results_first_submitted_qc>November 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 5, 2014</results_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown, Todd, M.D., Ph.D.</investigator_affiliation>
    <investigator_full_name>Todd T. Brown, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine and Epidemiology</investigator_title>
  </responsible_party>
  <keyword>AIDS</keyword>
  <keyword>HIV</keyword>
  <keyword>HAART</keyword>
  <keyword>Lipids</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>bone turnover</keyword>
  <keyword>inflammation</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took plave between November 2006 and September 2010 at 3 sites (Johns Hopkins University, Baltimore, MD;Veteranâ€™s Administration Greater Los Angeles Healthcare System (Los Angeles, CA), and the Georgetown University Hospital (Washington, DC). Participants were recruited from the HIV Clinics at these institutions.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LOVAZA</title>
          <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Corn oil placebo, plus dietary counselling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LOVAZA</title>
          <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Corn oil placebo, plus dietary counselling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="5.2"/>
                    <measurement group_id="B2" value="48.2" spread="8.0"/>
                    <measurement group_id="B3" value="49.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="47" upper_limit="52"/>
                    <measurement group_id="B2" value="48" lower_limit="41" upper_limit="52"/>
                    <measurement group_id="B3" value="49.5" lower_limit="45.5" upper_limit="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Triglyceride Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglyceride Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34" lower_limit="-149" upper_limit="9.5"/>
                    <measurement group_id="O2" value="40" lower_limit="-51" upper_limit="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" lower_limit="-31" upper_limit="23"/>
                    <measurement group_id="O2" value="-5" lower_limit="-25" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.80</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Non-HDL Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Non-HDL Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" lower_limit="-30" upper_limit="17"/>
                    <measurement group_id="O2" value="-9" lower_limit="-23" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL Cholesterol Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-2" upper_limit="4"/>
                    <measurement group_id="O2" value="-1" lower_limit="-6" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HOMA-IR From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HOMA-IR From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
          <population>Analysis done on all participants with available data</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" lower_limit="-0.51" upper_limit="3.6"/>
                    <measurement group_id="O2" value="0.94" lower_limit="-1.9" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4+ T-cell Counts From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4+ T-cell Counts From Baseline in the LOVAZA Group Compared to the Placebo Group</title>
          <population>Analysis done on all participants with available data</population>
          <units>cells/cc</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="-28" upper_limit="107"/>
                    <measurement group_id="O2" value="7" lower_limit="-42" upper_limit="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in hsCRP Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in hsCRP Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <population>Analysis done on all participants with available data</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-1.19" upper_limit="0.35"/>
                    <measurement group_id="O2" value="0.17" lower_limit="-0.38" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IL-6 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-6 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <population>Analysis done on all participants with available data</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" lower_limit="-1.89" upper_limit="0.13"/>
                    <measurement group_id="O2" value="0.19" lower_limit="-0.13" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TNF-a Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TNF-a Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <population>Analysis done on all participants with available data</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" lower_limit="-2.27" upper_limit="0.014"/>
                    <measurement group_id="O2" value="0.58" lower_limit="-1.15" upper_limit="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in sTNFR1 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in sTNFR1 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <population>Analysis done on all participants with available data</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" lower_limit="-91.8" upper_limit="69.8"/>
                    <measurement group_id="O2" value="-66.3" lower_limit="-189" upper_limit="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in sTNFR2 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in sTNFR2 Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <population>Analysis done on all participants with available data</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.5" lower_limit="-371" upper_limit="615"/>
                    <measurement group_id="O2" value="118" lower_limit="-499" upper_limit="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CTX Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CTX Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <population>Analysis done on all participants with available data</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.08" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.03" lower_limit="-0.06" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in P1NP Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in P1NP Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <population>Analysis done on all participants with available data</population>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.23" lower_limit="-12.6" upper_limit="-0.16"/>
                    <measurement group_id="O2" value="-2.12" lower_limit="-8.7" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Collagen ADP From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Collagen ADP From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <population>Analysis done on all participants with available data</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="-3" upper_limit="21"/>
                    <measurement group_id="O2" value="-6" lower_limit="-13" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Collagen Epinephrine From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis done on all participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>LOVAZA</title>
            <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo, plus dietary counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Collagen Epinephrine From Baseline in the LOVAZA Group Compared to the Placebo Group.</title>
          <population>Analysis done on all participants with available data</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="-6" upper_limit="39"/>
                    <measurement group_id="O2" value="-18" lower_limit="-46.5" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LOVAZA</title>
          <description>4 g/d of omega-3 fatty acid esters, plus dietary counseling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Corn oil placebo, plus dietary counselling
Omega-3 fatty acid administration: LOVAZA 1 gram capsules, 4 capsules daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointesitnal Side effects (dyspepsia, bloating, fishy taste)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Todd Brown, Associate Professor of Medicine and Epidemiology</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-502-2327</phone>
      <email>tbrown27@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

